Navigation
Navigation
User login
La Fundación para la Investigación del Hospital Universitario La fe de la Comunidad Valenciana
La Fundación para la Investigación del Hospital Universitario La fe de la Comunidad Valenciana

La Fundación para la Investigación del Hospital Universitario La fe de la Comunidad Valenciana

The Health Research Institute La Fe (Instituto Investigación Sanitaria [IIS] La Fe) carries out scientific and research activities with multidisciplinary and complementary research groups that have consolidated expertise in cellular and molecular biology, cell culture, functional analysis imaging, "omics" and clinical research. The Research group in Haematology is part of the Spanish Network of Cooperative Research in Cancer. Their main areas of interest include studying the prognostic impact of various molecular and genetic markers, genetic characterization and monitoring of minimal residual disease and studies on epigenetic pathways that regulate tumour proliferation in acute leukaemia and MDS, and the use of hematopoietic stem cell transplantation from umbilical cord blood for these disorders.

Our team

Description of the image
Description of the image

Prof. Guillermo Sanz, MD, PhD

Guillermo is a haematologist, head of Clinical Haematology at University Hospital La Fe and is the President of the Spanish cooperative group on MDS (GESMD) with more than 250 members from 100 participating hospitals/institutions and with a registry comprising clinical and biologic data from more than 10,000 MDS patients. The GESMD recently published the Spanish Guidelines for Diagnosis and Treatment of patients with MDS, which are widely accepted and used both in Spain and in Latin America. Prof. Sanz has made relevant contributions to the field of MDS, including reports at international meetings and publications in high impact factor journals.

Guillermo's role in MDS-RIGHT is to develop new predictive models for response to specific treatment modalities integrating clinical and molecular variables. Besides this he will use his extensive experience in the Spanish MDS study group and Registry for dissemination of relevant MDS guidelines to Spanish stakeholders. Also, patient recruitment and data collection for MDS-RIGHT will be coordinated by Sanz and his team.

Description of the image
Description of the image

Dr. Jose Cervera, PhD, MD

Jose is head of the Genetic and Cytogenetics Unit and member of the GESMD. He has clinical and research expertise in MDS and AML. The scientific work developed by Jose during the past two decades, although focusing on various aspects of haematological diseases, has been mainly addressed on the fields of clinical and biological characterization of AML and MDS. Jose has made relevant contributions to the field of MDS, including more than 300 reports at international meetings and publications in high impact factor journals. Among them, he has recently published the Spanish guidelines for management of patients with MDS.

Description of the image
Description of the image

Dr. Santiago Bonanad, MD

Santiago is head of the thrombosis and haemostatis Unit, treasurer of the GESMD and currently, part of its Board. His main interests are focused on epidemiology, registries, treatment and health economics and outcome research in MDS. He has made relevant contributions to the field of MDS, including reports at international meetings and publications in high impact factor journals. One of his main contributions to the literature in MDS has been the development of geriatric evaluation scales for patients with hematologic neoplasms (GAH Scale).

Description of the image
Description of the image

Dr. Esperanza Such, PhD

Esperanza is a senior lab researcher working for the Haematology Department at Genetic and Cytogenetics lab. She is a very active member of GESMD Group. She has a background in cytogenetic and molecular diagnosis of haematological malignancies. Her research has been focussed on MDS, mainly in CMML. She made relevant contributions to the field of MDS, including more than 100 reports at international meetings and publications in high IF journals. One of her main contributions to the literature in MDS has been the development of a prognostic scoring system for patients with CMML. In addition, she has recently published the Spanish guidelines of the management of patients with MDS. To date, Esperanza has addressed many different projects in order to the characterization of patients with hematologic malignancies by next generation sequencing. In all of them, potential genetic alterations in hematologic diseases have been discovered.

Description of the image
Description of the image

Dr. Mariam Ibáñez, PhD

Mariam is a junior lab researcher for the Haematology Department at Genetic and Cytogenetics lab. She has a background in genetic diagnosis and research of hematologic malignancies. She is member of GESMD group. She has participated in different projects focused on the identification of cancer-associated mutations in AML and MDS. To date, Mariam has addressed several projects in order to the characterization of patients with AML and MDS by next generation sequencing, where potential genetic alterations in hematologic diseases have been discovered. She made relevant contributions to the field of MDS, including reports at international meetings and publications in high impact factor journals.

Description of the image
Description of the image

David Pellicer

David is a senior project manager and is the data manager of the EUMDS registry in Spain.